Exelixis set to continue XL184 development despite BMS setback
This article was originally published in Scrip
Executive Summary
Exelixis is remaining upbeat despite Bristol-Myers Squibb's decision to return the development and commercialisation rights to its lead compound, the targeted anticancer XL184.